Fathom Divests LiveBy Assets to Move Concierge for $3 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Fathom announced the divesture of LiveBy assets to Move Concierge for $3 million. The Company expects to receive an additional $300,000 annually in contingent consideration based on data-sharing arrangements. The proceeds from the divestiture will support Fathom's growth initiatives. As part of the transaction, Fathom will retain access to the LiveBy platform for the next five years. In addition, Move Concierge has committed to extending its current suite of services to all Fathom agents. Both LiveBy and Move Concierge will make their services available to every agent and brokerage that licenses the IntelliAgent platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FTHM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FTHM
Wall Street analysts forecast FTHM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.520
Low
2.50
Averages
2.50
High
2.50
Current: 0.520
Low
2.50
Averages
2.50
High
2.50
About FTHM
Fathom Holdings Inc. is a national, technology-driven real estate services platform that integrates residential brokerage, mortgage, title, and SaaS offerings through its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, Real Results, and Verus Title. The Company's segments include Real Estate Brokerage, Mortgage and Technology. Its Real Estate Brokerage segment provides real estate brokerage services. The Company operates as a real estate brokerage company, working with real estate agents to help individuals purchase and sell residential and commercial properties, primarily in the South, Atlantic, Southwest, and Western parts of the United States. Its Mortgage segment provides residential loan origination and underwriting services. Its Technology segment provides SaaS solutions and data mining for third party customers and continues to develop its intelliAgent platform for use by its real estate agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fathom Holdings Receives Nasdaq Compliance Notice
- Compliance Notice: Fathom Holdings received a notice from Nasdaq for failing to timely file its quarterly report for the period ended March 31, 2026, indicating challenges in the company's financial transparency.
- Remediation Deadline: Nasdaq has given the company until July 21, 2026, to submit a compliance plan, and if accepted, the company may extend the deadline to November 11, 2026, providing additional time for compliance efforts.
- Impact on Securities Trading: Despite the compliance notice, Fathom stated that it has no immediate effect on the listing or trading of its securities on the Nasdaq Capital Market, indicating that the company can maintain market activity in the short term.
- Financial Statement Progress: Fathom is working diligently to finalize its financial statements and file the Form 10-Q as soon as practicable, demonstrating the company's commitment to restoring compliance and maintaining investor confidence and market reputation.
See More
Fathom Holdings Faces Nasdaq Compliance Issue
- Compliance Notice: Fathom Holdings received a notice from Nasdaq for failing to timely file its 10-Q report for the period ending March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1), which could negatively impact the company's market reputation and investor confidence.
- Rectification Deadline: The company must submit a compliance plan within 60 days, by July 21, 2026; if accepted, it may receive an extension of up to 180 days until November 11, 2026, with potential delisting risks if compliance is not achieved.
- Financial Statement Preparation: Fathom Holdings is diligently preparing its financial statements to file the 10-Q report as soon as possible, aiming to restore compliance within the stipulated timeframe to avoid adverse effects on operations and stock price.
- Market Impact: Although the notice does not immediately affect the listing or trading of the company's securities, failure to regain compliance in time could lead to delisting, thereby impacting investor confidence and the company's future financing capabilities.
See More
Fathom Holdings Faces Nasdaq Compliance Issue
- Compliance Notice: Fathom Holdings has received a notice from Nasdaq for failing to timely file its 10-Q report for the period ending March 31, 2026, which violates Nasdaq Listing Rule 5250(c)(1) and could jeopardize its listing status.
- Compliance Plan Deadline: The company is required to submit a plan to regain compliance within 60 days, by July 21, 2026; if accepted, it may receive an extension of up to 180 days until November 11, 2026, to achieve compliance.
- Potential Consequences: Failure to regain compliance in a timely manner could lead to the delisting of the company's securities from the Nasdaq Capital Market, negatively impacting investor confidence and the company's ability to raise capital.
- Financial Statement Progress: Fathom Holdings is diligently working to finalize its financial statements and file the 10-Q report as soon as possible to ensure compliance and mitigate long-term operational impacts.
See More
FATHOM RECEIVES STRATEGIC FUNDING FROM CVS HEALTH VENTURES TO BOOST ENTERPRISE-WIDE AUTONOMOUS CODING INITIATIVES
- Investment Announcement: Fathom has secured a strategic investment from CVS Health Ventures.
- Focus on Innovation: The funding aims to accelerate enterprise-wide autonomous coding solutions.
See More
Fathom Therapeutics Secures Funding Round Led by Chemistry, Alexandria Venture Investments, and NY Ventures from Empire State Development, Among Others
- Funding Sources: The funding for Fathom Therapeutics is led by Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- Investment Focus: The investments are aimed at advancing therapeutic innovations in the healthcare sector.
See More
Fathom Therapeutics, previously known as AtomMap, Secures $47 Million in Oversubscribed Series A Funding to Advance Physics and AI-Driven Small Molecule Development for Next-Gen Medicines
Funding Announcement: Fathom Therapeutics, formerly known as Atommap, has successfully raised $47 million in a recent funding round.
Research Focus: The funds will be utilized to advance their research in translating physics and AI-enabled small molecule design into next-generation medicines.
See More
Fathom Holdings Receives Nasdaq Compliance Notice
- Compliance Notice: Fathom Holdings received a notice from Nasdaq for failing to timely file its quarterly report for the period ended March 31, 2026, indicating challenges in the company's financial transparency.
- Remediation Deadline: Nasdaq has given the company until July 21, 2026, to submit a compliance plan, and if accepted, the company may extend the deadline to November 11, 2026, providing additional time for compliance efforts.
- Impact on Securities Trading: Despite the compliance notice, Fathom stated that it has no immediate effect on the listing or trading of its securities on the Nasdaq Capital Market, indicating that the company can maintain market activity in the short term.
- Financial Statement Progress: Fathom is working diligently to finalize its financial statements and file the Form 10-Q as soon as practicable, demonstrating the company's commitment to restoring compliance and maintaining investor confidence and market reputation.
See More
Fathom Holdings Faces Nasdaq Compliance Issue
- Compliance Notice: Fathom Holdings received a notice from Nasdaq for failing to timely file its 10-Q report for the period ending March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1), which could negatively impact the company's market reputation and investor confidence.
- Rectification Deadline: The company must submit a compliance plan within 60 days, by July 21, 2026; if accepted, it may receive an extension of up to 180 days until November 11, 2026, with potential delisting risks if compliance is not achieved.
- Financial Statement Preparation: Fathom Holdings is diligently preparing its financial statements to file the 10-Q report as soon as possible, aiming to restore compliance within the stipulated timeframe to avoid adverse effects on operations and stock price.
- Market Impact: Although the notice does not immediately affect the listing or trading of the company's securities, failure to regain compliance in time could lead to delisting, thereby impacting investor confidence and the company's future financing capabilities.
See More
Fathom Holdings Faces Nasdaq Compliance Issue
- Compliance Notice: Fathom Holdings has received a notice from Nasdaq for failing to timely file its 10-Q report for the period ending March 31, 2026, which violates Nasdaq Listing Rule 5250(c)(1) and could jeopardize its listing status.
- Compliance Plan Deadline: The company is required to submit a plan to regain compliance within 60 days, by July 21, 2026; if accepted, it may receive an extension of up to 180 days until November 11, 2026, to achieve compliance.
- Potential Consequences: Failure to regain compliance in a timely manner could lead to the delisting of the company's securities from the Nasdaq Capital Market, negatively impacting investor confidence and the company's ability to raise capital.
- Financial Statement Progress: Fathom Holdings is diligently working to finalize its financial statements and file the 10-Q report as soon as possible to ensure compliance and mitigate long-term operational impacts.
See More
FATHOM RECEIVES STRATEGIC FUNDING FROM CVS HEALTH VENTURES TO BOOST ENTERPRISE-WIDE AUTONOMOUS CODING INITIATIVES
- Investment Announcement: Fathom has secured a strategic investment from CVS Health Ventures.
- Focus on Innovation: The funding aims to accelerate enterprise-wide autonomous coding solutions.
See More
Fathom Therapeutics Secures Funding Round Led by Chemistry, Alexandria Venture Investments, and NY Ventures from Empire State Development, Among Others
- Funding Sources: The funding for Fathom Therapeutics is led by Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- Investment Focus: The investments are aimed at advancing therapeutic innovations in the healthcare sector.
See More
Fathom Therapeutics, previously known as AtomMap, Secures $47 Million in Oversubscribed Series A Funding to Advance Physics and AI-Driven Small Molecule Development for Next-Gen Medicines
Funding Announcement: Fathom Therapeutics, formerly known as Atommap, has successfully raised $47 million in a recent funding round.
Research Focus: The funds will be utilized to advance their research in translating physics and AI-enabled small molecule design into next-generation medicines.
See More
